Comparative Pharmacology
Head-to-head clinical analysis: FLECTOR versus PENNSAID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLECTOR versus PENNSAID.
FLECTOR vs PENNSAID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing pain, inflammation, and fever.
Apply 1 sachet (10 g of 1.3% gel, equivalent to 130 mg diclofenac epolamine) to the affected area twice daily. Maximum duration: 7 days.
Apply 1 sachet (50 mg diclofenac sodium) to each affected knee twice daily; total daily dose not to exceed 100 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 1.8–3.5 hours (mean 2.5 hours) in healthy adults; no significant accumulation with repeated dosing
Terminal elimination half-life is approximately 74 hours (range 53–97 hours) for diclofenac epolamine topical system. With repeated dosing, steady state is reached within 7 days.
Renal (approximately 50% as unchanged drug and metabolites), biliary/fecal (approximately 40% as metabolites)
Primarily renal excretion of metabolites and conjugates; less than 1% excreted unchanged. Biliary/fecal excretion accounts for approximately 1%.
Category C
Category C
Topical NSAID
Topical NSAID